Phathom Pharmaceuticals Dirección

Dirección controles de criterios 4/4

El CEO de Phathom Pharmaceuticals es Terrie Curran , nombrado en Dec 2019, tiene una permanencia de 4.92 años. compensación anual total es $3.41M, compuesta por 20.2% salario y 79.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.25% de las acciones de la empresa, por valor de $1.49M. La antigüedad media del equipo directivo y de la junta directiva es de 4.9 años y 5 años, respectivamente.

Información clave

Terrie Curran

Chief Executive Officer (CEO)

US$3.4m

Compensación total

Porcentaje del salario del CEO	20.2%
Permanencia del CEO	4.9yrs
Participación del CEO	0.2%
Permanencia media de la dirección	4.9yrs
Promedio de permanencia en la Junta Directiva	5yrs

Actualizaciones recientes de la dirección

Recent updates

Following Up On Phathom Pharmaceuticals

Sep 03

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Jun 26

Phantom Pharma completes enrollment in late-stage study of lead candidate in esophagus inflammation disorder

Nov 30

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Terrie Curran en comparación con los beneficios de Phathom Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$339m
Jun 30 2024	n/a	n/a	-US$297m
Mar 31 2024	n/a	n/a	-US$247m
Dec 31 2023	US$3m	US$688k	-US$202m
Sep 30 2023	n/a	n/a	-US$177m
Jun 30 2023	n/a	n/a	-US$185m
Mar 31 2023	n/a	n/a	-US$195m
Dec 31 2022	US$5m	US$650k	-US$198m
Sep 30 2022	n/a	n/a	-US$179m
Jun 30 2022	n/a	n/a	-US$164m
Mar 31 2022	n/a	n/a	-US$150m
Dec 31 2021	US$6m	US$568k	-US$144m
Sep 30 2021	n/a	n/a	-US$162m
Jun 30 2021	n/a	n/a	-US$159m
Mar 31 2021	n/a	n/a	-US$144m
Dec 31 2020	US$5m	US$499k	-US$129m
Sep 30 2020	n/a	n/a	-US$173m
Jun 30 2020	n/a	n/a	-US$207m
Mar 31 2020	n/a	n/a	-US$274m
Dec 31 2019	US$4m	US$42k	-US$255m

Compensación vs. Mercado: La compensación total ($USD3.41M) de Terrie está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD3.22M).

Compensación vs. Ingresos: La compensación de Terrie ha sido consistente con los resultados de la empresa en el último año.

CEO

Terrie Curran (55 yo)

4.9yrs

Permanencia

US$3,411,022

Compensación

Ms. Terrie J. Curran is a Director of Phathom Pharmaceuticals, Inc. since August 2019 and serves as its Chief Executive Officer since December 02, 2019 and also serves as its President. Ms. Curran serves a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Terrie Curran	President	4.9yrs	US$3.41m	0.25% $ 1.5m
David Socks	Co-Founder & Director	no data	US$266.34k	1.79% $ 10.7m
Azmi Nabulsi	Co-Founder & COO	5.7yrs	US$2.04m	1.33% $ 8.0m
Molly Henderson	Chief Financial & Business Officer	2.6yrs	US$1.87m	0.071% $ 426.1k
Aditya Kohli	Co-Founder	no data	US$319.65k	sin datos
Paul Cocja	Chief People Officer	less than a year	sin datos	sin datos
Tom Harris	Chief Development Sciences Officer	no data	sin datos	sin datos
Eckhard Leifke	Chief Medical Officer	4.9yrs	sin datos	sin datos
Martin Gilligan	Chief Commercial Officer	4.8yrs	sin datos	sin datos

4.9yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de PHAT se considera experimentado (4.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Terrie Curran	President	5.3yrs	US$3.41m	0.25% $ 1.5m
David Socks	Co-Founder & Director	6.8yrs	US$266.34k	1.79% $ 10.7m
Michael Cola	Independent chairman of the Board	5.2yrs	US$331.34k	0.027% $ 165.0k
Heidi Fields	Independent Director	5.2yrs	US$287.17k	0.013% $ 79.0k
James Topper	Independent Director	2.2yrs	US$267.14k	0.032% $ 189.6k
Frank Karbe	Independent Director	2.6yrs	US$283.84k	0.050% $ 298.5k
Asit Parikh	Independent Director	4.9yrs	US$279.67k	0.080% $ 482.9k
Mark Stenhouse	Independent Director	4.7yrs	US$283.84k	0.013% $ 79.0k

5.0yrs

Permanencia media

56.5yo

Promedio de edad

Junta con experiencia: La junta directiva de PHAT se considera experimentada (5 años de antigüedad promedio).

Phathom Pharmaceuticals Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

President recently sold US$397k worth of stock

Phathom Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

President recently sold US$154k worth of stock

Independent Director recently bought US$59k worth of stock

President recently bought US$101k worth of stock

High number of new directors

Recent updates

Consensus revenue estimates increase by 16%

New minor risk - Share price stability

Price target increased by 9.6% to US$24.43

Phathom Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Following Up On Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $129.999992 million.

Phathom Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $129.999992 million.

Consensus EPS estimates fall by 14%, revenue upgraded

New minor risk - Profitability

Phathom Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

President recently sold US$397k worth of stock

Phathom Pharmaceuticals Announces FDA Approval of Vquezna®? (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GermanyD in Adults

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Consensus EPS estimates fall by 12%

Phathom Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

President recently sold US$154k worth of stock

Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion

New minor risk - Profitability

Forecast to breakeven in 2026

Phathom Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Phathom Pharmaceuticals Announces Voquezna® (Vonoprazan) Tablets for Erosive Gerd and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

Consensus revenue estimates decrease by 45%

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

New minor risk - Share price stability

Phathom Pharmaceuticals, Inc. Announces Commercial Availability of VOQUEZNA®? (Vonoprazan) Tablets

New major risk - Negative shareholders equity

Independent Director recently bought US$59k worth of stock

Phathom Pharmaceuticals, Inc. Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for Voquezna Triple Pak (Vonoprazan, Amoxicillin, Clarithromycin) and Voquezna Dual Pak (Vonoprazan, Amoxicillin) for the Treatment of H. Pylori Infection in Adults

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive Germany

Consensus EPS estimates upgraded to US$3.83 loss, revenue downgraded

New major risk - Financial position

Price target increased by 14% to US$18.67

Phathom Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $130.71875 million.

Consensus EPS estimates upgraded to US$4.52 loss

President recently bought US$101k worth of stock

Consensus revenue estimates decrease by 66%, EPS upgraded

Price target decreased by 12% to US$18.20

Phathom Pharmaceuticals, Inc. Approves in the U.S. for the Treatment of H. Pylori Infection, and Its Pending New Drug Application (NDA) for Vonoprazan for the Treatment of Erosive Esophagitis

Phathom Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease

Phathom Pharmaceuticals, Inc. Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis

Price target decreased to US$26.20

High number of new directors

Phathom Pharmaceuticals, Inc. Completes Patient Enrollment in Its Phalcon-Nerd Daily Dosing Phase 3 Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease

Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

Phathom Pharmaceuticals, Inc Appoints James Topper to its Board of Directors

Phathom Pharmaceuticals GAAP EPS of -$1.33 misses by $0.30

Consensus forecasts updated

The Prognosis For Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc. Announces FDA Acceptance for Filing of Vonoprazan NDA for Treatment of Erosive Esophagitis

Phathom Pharmaceuticals, Inc. Presents Data on Novel Potassium-Competitive Acid Blocker Vonoprazan from Range of Studies at Digestive Disease Week 2022

Price target decreased to US$42.80

Co-Founder & COO recently bought US$163k worth of stock

Price target decreased to US$46.20

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

High number of new and inexperienced directors

Phathom Pharmaceuticals, Inc. Appoints Frank Karbe to its Board of Directors

Phathom Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)

Phathom Pharmaceuticals: Undiscovered Gem

Price target decreased to US$53.40

Forecast to breakeven in 2024

High number of new and inexperienced directors

Phathom Pharmaceuticals, Inc. Announces Results from VONO-103

Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection

Phathom Pharmaceuticals, Inc. Announces FDA Grants Additional QIDP Designations to Vonoprazan Triple Therapy and Vonoprazan Dual Therapy, Each Containing Amoxicillin Capsules, for the Treatment of H. Pylori Infection

Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter Pylori (H. Pylori) Infection; Study Met All Primary and Secondary Endpoints

Phathom Pharmaceuticals, Inc. Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial

Phathom Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $94.5 million.